Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Descriptive
Exchange
Industry
Country
Active:none
| Company | Rating | |||||
|---|---|---|---|---|---|---|
| Loading data… | ||||||
Saved screens and full data - with a subscription
Subscribe to save filters and unlock all columns and ratings.
Subscribe - €24.90/mo